TKI resistance
Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells
... of resistance to EGFR-TKI represent critical problems to be ...EGFR-TKI resistance after relatively prolonged treatment both in vitro and in vivo, although it is not relevant to drug ...
18
FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators
... that TKI responsiveness can be highly dependent upon expression of the proapoptotic BH3-only protein BIM, and a very recent study identified a common BIM deletion polymorphism as a mediator of intrinsic ...
5
Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression
... in TKI resistant lung adenocarcinoma cells occurred through an EGFR-independent ...confer TKI resistance ...confer TKI resistance in lung adenocarcinoma cells ...in TKI ...
10
<p>Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review</p>
... acquired resistance invariably happened in about 1 year after ...EGFR-TKI resistance cases. 2 Third-generation EGFR- TKI is a powerful drug against these ...drug resistance is also ...
7
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
... chemotherapy resistance or endo- crine therapy resistance [15, ...acquired resistance (HCC827GR) and cell line with pri- mary resistance (H1975)) than in the cell lines with sen- sitive EGFR ...
20
Targeting BCR-ABL-Independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition
... showed that single-agent treatment was similarly effective as when combined with complete BCR-ABL inhibition (Figure 3B). Subsequent target association analysis enriched for and high- lighted microtubule, proteasome, and ...
12
FAM83A confers EGFR TKI resistance in breast cancer cells and in mice
... this resistance remain largely unknown. We hypothesized that resistance may originate, at least in part, from molecular alterations that activate signaling downstream of ...conferring resistance to ...
11
A case of<em> EGFR</em> mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with <em>MET</em> amplification and epithelial-to-mesenchymal transition
... develop resistance to ...acquired resistance to EGFR-TKI with MET amplification and epithelial-to-mesenchymal transition ...that resistance to EGFR-TKI might be caused by MET ...
5
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
... Very rare, resistance mechanism unclear. The variant L747S occasionally reported both as secondary TKI- resistant mutant in the setting of acquired TKI- resistance and as de novo mu[r] ...
70
Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors by Transformation to Small Cell Lung Cancer in an EGFR-mutant Patient
... the resistance mechanisms ...EGFR-TKI resistance may develop and for which patient to do a ...secondary TKI resistance are single-agent treatment with EGFR-TKI for EGFR mutations ...
5
Tki sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant alk+ tumors
... Accordingly, resistance is not due to steric hindrance of drug binding, but rather promotion of ALK’s active conformation indicated by accelerated autophosphorylation [10, 37, ...a TKI-resistance and ...
15
Review Article The E3 ubiquitin ligase NEDD4 mediates EGFR-TKI acquired resistance in non-small cell lung cancer
... acquired resistance to EGFR-TKI with 12 mo- nths [5]. Resistance to EGFR-TKI includes vari- ous mechanisms, such as the secondary muta- tion (T790M), amplification of c-met, RAS mu- tation, ...
7
Heterogeneity of resistance mutations detectable by next- generation sequencing in TKI-treated lung adenocarcinoma
... for TKI therapy in NSCLCs ...of TKI therapy ...following TKI therapy, presumably as a resistance ...acquired TKI resistance was also supported by a recent study demonstrating a ...
12
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
... this TKI therapy after 9–15 months of treatment ...acquired resistance to the first- and second-generation TKI, in which the sec- ondary Threonine-790-Methionine substitution muta- tion (T790M) in ...
18
Original Article Pemetrexed combined with cisplatin for patients with EGFR-TKI resistant advanced lung cancer
... Inclusion criteria: Patients pathologically diag- nosed with advanced lung cancer; Patients pathologically diagnosed as stage III or IV; Patients that met the criteria [8] for acquired EGFR-TKI resistance. ...
8
A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment
... EGFR-TKI resistance have shown that the T790M mutation within the EGFR gene is present in approximately half of the patients who develop resist- ance to a first- or second-generation EGFR-TKI [1, ...
5
A NOX2/Egr-1/Fyn pathway delineates new targets for TKI- resistant malignancies
... of TKI-resistant cell lines and blast crisis LSCs reveal a number of different pathways through which this might occur including NFκB, PIN1, or PRKCB (Figure ...treatment resistance in CML [68, ...treatment ...
16
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
... with TKI or cetuximab inhibition, which are strikingly ...of TKI inhibition on the malignant phenotype is indeed the integration of several variables: the onco- genic potency of the targeted receptor, the ...
15
Gillis_unc_0153D_16817.pdf
... to TKI use. Due to the relatively small number of patients prescribed a TKI in our cohort, we have insufficient evidence to draw a definitive conclusion regarding the possible association between TKI ...
186
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
... induce resistance to EGFR TKI by promoting activation of downstream pathways, independent of EGFR ...induce resistance to EGFR TKI in EGFR-mutant models in vitro ...acquired resistance ...
11